Print | Email Page

Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 million

April 2019

Jones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.

For additional information about this matter, please contact: Joshua Berick, Sebastian Martinek Ph.D.

Client(s): Royalty Pharma